Combination of temozolomide with immunocytokine F16–IL2 for the treatment of glioblastoma

BACKGROUND: Glioblastoma patients are still not cured by the treatments available at the moment. We investigated the therapeutic properties of temozolomide in combination with F16–IL2, a clinical-stage immunocytokine consisting of human interleukin (IL)-2 fused to the human antibody F16, specific to...

Descripción completa

Detalles Bibliográficos
Autores principales: Pedretti, M, Verpelli, C, Mårlind, J, Bertani, G, Sala, C, Neri, D, Bello, L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966626/
https://www.ncbi.nlm.nih.gov/pubmed/20736949
http://dx.doi.org/10.1038/sj.bjc.6605832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966626/
https://www.ncbi.nlm.nih.gov/pubmed/20736949
http://dx.doi.org/10.1038/sj.bjc.6605832

Ejemplares similares